Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4U72A)

Drug Name
CGS-26393 Drug Info
Synonyms
Cgs 26393; Cgs-26393; 154116-34-4; AC1L2SSW; cgs26393; CHEMBL36795; SCHEMBL8921559; CTK4C8116; DTXSID00165542; 2-Biphenyl-4-yl-1-(1H-tetrazol-5-yl)ethylaminoethyl phosphonic acid; (S)-Diphenyl (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)phosphonate; (1S)-N-(diphenoxyphosphorylmethyl)-2-(4-phenylphenyl)-1-(2H-tetrazol-5-yl)ethanamine; Phosphonic acid, (((2-(1,1'-biphenyl)-4-yl-1-(1H-tetrazol-5-yl)ethyl)amino)methyl)-, diphenyl ester, (S)-; Phosphonic acid,P-[[[(1S)-2-[1,1'-biphenyl]-4-yl-1-(2H-tetraz
Indication
Disease Entry ICD 11 Status REF
Heart disease BA41-BA42 Terminated [1]
Cross-matching ID
PubChem CID
127883
CAS Number
CAS 154116-34-4
TTD Drug ID
DM4U72A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Neutral endopeptidase (MME)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LCZ696 DMLFX7K Heart failure BD10-BD13 Approved [3]
Candoxatril DMHJCGV Hypertension BA00-BA04 Phase 3 [4]
Gallopamil DMXBR27 Asthma CA23 Phase 2 [5]
SLV 306 DMCDON3 Acute decompensated heart failure BD1Z Phase 2 [6]
SLV-334 DMXCJKY Brain injury NA07.Z Phase 2 [7]
VX-15 DMLWM4G Huntington disease 8A01.10 Phase 2 [8]
Sampatrilat DMXTOVE Hypotension BA20-BA21 Phase 2 [9]
SLV-338 DM7WKTM Cardiovascular disease BA00-BE2Z Phase 1 [10]
GW-796406 DMQ46DN Hypotension BA20-BA21 Phase 1 [5]
Debio 0827 DMQIEFB Chronic pain MG30 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neutral endopeptidase (MME) TT5TKPM NEP_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005940)
2 Oral administration of an inhibitor of endothelin-converting enzyme attenuates cerebral vasospasm following experimental subarachnoid haemorrhage in rabbits. Clin Sci (Lond). 2002 Aug;103 Suppl 48:414S-417S.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
5 Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
6 The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
7 Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
10 Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15.
11 Clinical pipeline report, company report or official report of Debiopharm (2011).